Compared to Estimates, Teleflex (TFX) Q2 Earnings: A Look at Key Metrics

Core Viewpoint - Teleflex reported a revenue of $749.69 million for the quarter ended June 2024, showing a year-over-year increase of 0.9% and an EPS of $3.42, slightly up from $3.41 a year ago, but below the Zacks Consensus Estimate of $763.39 million, resulting in a revenue surprise of -1.79% [1] Revenue Performance - Geographic Revenues in the Americas reached $426.80 million, slightly below the average estimate of $432.19 million, reflecting a year-over-year change of +0.5% [3] - Geographic Revenues in Asia totaled $87 million, marginally below the estimated $87.90 million, with a year-over-year increase of +0.4% [4] - Geographic Revenues in EMEA were reported at $147.10 million, significantly lower than the estimated $157.16 million, indicating a year-over-year decline of -0.5% [5] Segment Revenues - Net Revenues from Vascular Access were $181.10 million, close to the average estimate of $181.31 million, with a year-over-year increase of +4.2% [6] - Net Revenues from Interventional reached $141.20 million, exceeding the estimate of $137.89 million, marking a year-over-year growth of +13.1% [7] - Net Revenues from Anesthesia were reported at $102.50 million, slightly below the estimate of $104.01 million, with a year-over-year increase of +1.7% [8] - Revenues from OEM (Original Equipment Manufacturer and Development Services) were $88.80 million, surpassing the estimate of $88.27 million, reflecting a year-over-year increase of +5.6% [9] - Net Revenues from Interventional Urology were $83.10 million, slightly below the estimate of $83.48 million, with a year-over-year increase of +6.8% [10] - Net Revenues from Other segments were reported at $41.70 million, significantly below the estimate of $55.13 million, indicating a year-over-year decline of -45.1% [11] - Net Revenues from Surgical were $111.30 million, close to the estimate of $111.50 million, with a year-over-year increase of +5% [12] Stock Performance - Teleflex shares have returned +4.5% over the past month, outperforming the Zacks S&P 500 composite's +1.1% change, and the stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [12]